Home / Auditor changes / Crinetics Pharmaceuticals, Inc.
Filed 2026-03-03 路 Form 8-K 路 Accession 0001658247-26-000017 mid
Price before filing: $40.68 (2026-03-02 close, split/dividend-adjusted)
Market cap at flag: $4.18B (2026-03-03) 路 Latest: $8.97B (2026-09-02)
| Window | CRNX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -8.5% | -4.2% | -4.3% | 2026-04-02 |
| 90 days | -15.1% | +10.8% | -26.0% | 2026-06-01 |
| 180 days | +108.8% | +12.3% | +96.5% | 2026-08-31 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider sold $138K (1 sale)
30 days after: 6 insiders sold $2.2M (10 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | Kalofonos Isabel Chief Commercial Officer | Sale | 2,500 | $55.00 | $138K | yes | Form 4 |
| 2026-03-03: red flag filed | |||||||
| 2026-03-03 | Okey Stephanie Director | Sale | 3,000 | $39.67 | $119K | yes | Form 4 |
| 2026-03-03 | Schilke Tobin Chief Financial Officer | Sale | 6,713 | $39.67 | $266K | yes | Form 4 |
| 2026-03-12 | Vivaldi Coelho Rogerio Director | Sale | 4,477 | $36.08 | $162K | yes | Form 4 |
| 2026-03-12 | Vivaldi Coelho Rogerio Director | Sale | 523 | $36.77 | $19K | yes | Form 4 |
| 2026-03-16 | Betz Stephen F. Chief Scientific Officer | Sale | 6,371 | $37.11 | $236K | yes | Form 4 |
| 2026-03-16 | Betz Stephen F. Chief Scientific Officer | Sale | 4,241 | $37.77 | $160K | yes | Form 4 |
| 2026-03-16 | Knight Jeff E. Chief Operating Officer | Sale | 5,950 | $37.11 | $221K | yes | Form 4 |
| 2026-03-16 | Knight Jeff E. Chief Operating Officer | Sale | 3,961 | $37.77 | $150K | yes | Form 4 |
| 2026-03-16 | Struthers Richard Scott President & CEO, Director | Sale | 13,196 | $37.11 | $490K | yes | Form 4 |
| 2026-03-16 | Struthers Richard Scott President & CEO, Director | Sale | 8,785 | $37.77 | $332K | yes | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-03 to 2026-04-02. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"(the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: dismissed
Disagreements reported: no
Former auditor: BDO USA, P.C. · New auditor: PricewaterhouseCoopers LLP
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.